Zimmer Biomet (NYSE:ZBH) Announces Earnings Results

Zimmer Biomet (NYSE:ZBH) announced its earnings results on Wednesday. The medical equipment provider reported $1.90 EPS for the quarter, beating analysts’ consensus estimates of $1.88 by $0.02, FiscalAI reports. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The firm had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2.04 billion. During the same quarter in the prior year, the firm earned $1.90 EPS. Zimmer Biomet’s quarterly revenue was up 3.1% on a year-over-year basis.

Here are the key takeaways from Zimmer Biomet’s conference call:

• Zimmer Biomet reported 3.7% constant-currency sales growth, with hips up 7%, S.E.T. up 7.1%, and technology, data, bone cement, and surgical up 13%. The company said two-thirds of its portfolio grew at upper-single-digit or double-digit rates.
• The company raised its 2026 organic constant-currency sales growth outlook to 3%–3.5% and adjusted EPS guidance to $8.50–$8.60. It cited stronger-than-expected performance and expects full-year free cash flow to grow 9%–11%.
• Knee sales declined 2.6% in constant currency, amid U.S. sales-force transition and competitive pressure, with China also weighing on results. Management expects near-term pressure to continue and acknowledged the transition’s final stage carries higher risk.
• Zimmer Biomet plans to submit Monogram’s 510(k) application soon and expects a potential launch in the first half of 2027, ahead of its prior timeline; the timing remains subject to FDA approval. Management views the system as a potential growth catalyst alongside its existing robotics offerings.
• Third-quarter adjusted EPS was flat at $1.90, while adjusted operating margin fell 140 basis points to 25.1%, reflecting investment in the U.S. commercial organization and higher manufacturing costs.

Zimmer Biomet Trading Up 14.8%

ZBH stock traded up $14.38 on Wednesday, hitting $111.44. 3,206,353 shares of the company were exchanged, compared to its average volume of 2,245,582. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. The stock has a market capitalization of $21.26 billion, a price-to-earnings ratio of 27.09, a price-to-earnings-growth ratio of 2.34 and a beta of 0.50. Zimmer Biomet has a twelve month low of $79.12 and a twelve month high of $112.55. The business’s fifty day moving average is $94.71 and its two-hundred day moving average is $91.78.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet’s dividend payout ratio is 23.36%.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ZBH. UBS Group reaffirmed a “buy” rating and set a $120.00 price target on shares of Zimmer Biomet in a research note on Thursday, August 6th. Canaccord Genuity Group boosted their price target on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a report on Monday, August 10th. Wall Street Zen raised Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday. Sanford C. Bernstein lifted their price objective on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a research report on Thursday, August 6th. Finally, Weiss Ratings upgraded Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, September 14th. Seven equities research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $104.47.

Insiders Place Their Bets

In other news, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Chad Phipps sold 3,000 shares of the business’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $98.35, for a total transaction of $295,050.00. Following the sale, the insider directly owned 65,231 shares of the company’s stock, valued at $6,415,468.85. This represents a 4.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.28% of the stock is owned by company insiders.

More Zimmer Biomet News

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter revenue was $2.063 billion, up 3.1% year over year, while adjusted earnings of $1.90 per share beat analyst estimates. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Zimmer Biomet raised its full-year 2026 outlook. Strong Hips and S.E.T. sales helped offset softness elsewhere, supporting investor optimism and the stock’s move to a 52-week high. Zimmer Biomet Lifts Annual Growth Despite Challenging Knee Market
• Neutral Sentiment: Adjusted EPS was unchanged from a year earlier. The reported diluted EPS figure was $1.00, down 13.8%, reflecting a less favorable picture on a GAAP basis than the adjusted result. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Negative Sentiment: Knee-market weakness and margin pressure remain headwinds, partially offsetting growth in Hips and S.E.T. Zimmer Biomet Stock Up on Q3 Earnings & Revenue Beat, ’26 View Up

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.